KAMADA » MEDIA » NEWS

NEWS


Kamada announces FDA acceptance of Inhaled AAT program path forward

Press Release / Apr. 16, 2019

Kamada announced today receipt of a letter from the U.S. Food and Drug Administration (FDA or the Agency) stating that the Company has satisfactorily addressed the concerns and questions regarding its Inhaled Alpha-1-Antitrypsin (Inhaled AAT) program for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), previously communicated by the Agency.

Kamada Awarded the Israeli Outstanding Exporter Award for 2017

Press Release / Mar. 14, 2019

Kamada announced today that it has been awarded the Israeli Outstanding Exporter Award for 2017 by the Foreign Trade Department of the Israeli Ministry of Economy and Industry. The Company received the award for the continued growth demonstrated in its export revenues.

Kamada Files Annual Report for the Year Ended December 31, 2018

Press Release / Feb. 27, 2019

Kamada today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”).

Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2018

Press Release / Feb. 12, 2019

Kamada announced today financial results for the three and 12-months
ended December 31, 2018.

Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Press Release / Feb. 7, 2019

Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test.
Top-line Results Anticipated in H2 2019

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12

Press Release / Feb. 5, 2019

Kamada management will host an investment community conference call on Tuesday, February 12 at 8:30am Eastern Time to discuss these results and answer questions. 

Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development

Press Release / Jan. 30, 2019

announced today the appointment of Michal Ayalon, Ph.D., as Vice President of Research and Development.  She will oversee all of Kamada's R&D and IP activities, and report directly to Amir London, Kamada’s Chief Executive Officer.

Dr. Ayalon will succeed Liliana Bar, Ph.D. who has served as Kamada’s VP R&D since 2012 and is retiring next month.  

Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018

Press Release / Jan. 2, 2019

Kamada announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018. Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million. Total revenue for full-year 2018 is expected to be between $113 million and $115 million.

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018

Press Release / Nov. 12, 2018

Kamadad announced today financial results for the three and nine months ended September 30, 2018.

Kamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development

Press Release / Oct. 24, 2018

Kamada announced today the appointment of Eitan Kyiet as Vice President of Business Development. Mr. Kyiet has over 20 years of experience in business development, strategic operations and corporate law, with a significant portion of his career spent in the life sciences industry. He will lead Kamada's business development and strategic commercial activities, with a focus on advancing market opportunities for the Company's products. Mr. Kyiet will report directly to Amir London, Kamada’s Chief Executive Officer.

out of 168 items.